TIPE2 Antibody [A15H13]

Catalog No.: F7513

Application: Reactivity: Human

Lane 1: THP-1

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:30 IHC1:100 IF1:50

Application
WB, IP, IHC, IF

Source
Rabbit Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
20 kDa 18 kDa, 36 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
TIPE2 Antibody [A15H13] detects endogenous levels of total TIPE2 protein.

Clone
A15H13

Synonym(s)
Tumor necrosis factor alpha-induced protein 8-like protein 2; TIPE2; TNF alpha-induced protein 8-like protein 2; TNFAIP8-like protein 2; Inflammation factor protein 20; TNFAIP8L2

Background
TNF‑α–induced protein 8–like 2 (TIPE2; TNFAIP8L2) is a cytosolic immune‑regulatory protein of the TNFAIP8/TIPE family that functions as a negative modulator of innate and adaptive immune signaling in myeloid and lymphoid cells. The protein is constitutively expressed in macrophages, NK cells, and T lymphocytes and does not form a stable, pre‑assembled complex but instead engages membrane‑proximal and signaling‑adapter molecules to restrain NF‑κB and MAPK pathway activation. TIPE2 interacts with and dampens the activity of key kinases and adaptors in these cascades, including components that regulate IKK and JNK, thereby limiting the production of pro‑inflammatory cytokines and preventing excessive immune activation under homeostatic and challenge conditions. Reduced TIPE2 expression or loss‑of‑function exacerbates inflammatory pathology, as seen in models of colitis and arthritis, whereas forced overexpression of TIPE2 suppresses inflammatory signaling and ameliorates tissue damage, acting as a checkpoint in immune‑mediated diseases. TIPE2 exerts a dual, context‑dependent function, inhibiting antitumor immunity in some solid‑tumor microenvironments by enhancing immunosuppressive cell populations and dampening cytotoxic responses, yet in certain colitis‑associated cancer models, it can act as a colonocyte‑intrinsic tumor suppressor by restraining inflammation‑driven proliferation.

Background

TNF‑α–induced protein 8–like 2 (TIPE2; TNFAIP8L2) is a cytosolic immune‑regulatory protein of the TNFAIP8/TIPE family that functions as a negative modulator of innate and adaptive immune signaling in myeloid and lymphoid cells. The protein is constitutively expressed in macrophages, NK cells, and T lymphocytes and does not form a stable, pre‑assembled complex but instead engages membrane‑proximal and signaling‑adapter molecules to restrain NF‑κB and MAPK pathway activation. TIPE2 interacts with and dampens the activity of key kinases and adaptors in these cascades, including components that regulate IKK and JNK, thereby limiting the production of pro‑inflammatory cytokines and preventing excessive immune activation under homeostatic and challenge conditions. Reduced TIPE2 expression or loss‑of‑function exacerbates inflammatory pathology, as seen in models of colitis and arthritis, whereas forced overexpression of TIPE2 suppresses inflammatory signaling and ameliorates tissue damage, acting as a checkpoint in immune‑mediated diseases. TIPE2 exerts a dual, context‑dependent function, inhibiting antitumor immunity in some solid‑tumor microenvironments by enhancing immunosuppressive cell populations and dampening cytotoxic responses, yet in certain colitis‑associated cancer models, it can act as a colonocyte‑intrinsic tumor suppressor by restraining inflammation‑driven proliferation.

References
[1] Liu R, et al. Front Immunol. 2019 Sep 24;10:2284. [2] Xu L, et al. J Immunol. 2024 Mar 1;212(5):755-763.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%